by Neoteryx | 2 min read
When using immunosuppressive therapy drugs as an organ transplant recipient, it is crucial to effectively and consistently monitor drug levels. This requires therapeutic drug monitoring and an understanding of requirements …
Read Storyby Neoteryx | 2 min read
Therapeutic drug monitoring (TDM) immunosuppressants are a critical component of post-tissue and organ transplantation therapy. This is because ISP drugs have high intra- and inter-subject variability and a narrow therapeutic …
Read Storyby Neoteryx | 2 min read
When administering immunosuppressants, clinicians need to individualize a patient’s drug therapy. The goal is to attain an optimal balance between therapeutic efficacy and the probability of adverse effects. Patients present …
Read Storyby Neoteryx | 2 min read
For many organ transplant patients, immunosuppressant monitoring is a fact of life. But that does not mean that it cannot be significantly improved. For proof, look no further than the …
Read Storyby Neoteryx | 3 min read
At the 2019 meeting of the American Transplant Congress, held this year in Boston, scientists from the Oslo University Hospital, Rikshospitalet presented exciting findings regarding more patient-centered AUC-monitoring of tacrolimus, …
Read Storyby Neoteryx | 2 min read
Capillary blood microsampling is a technique that has made collection and analysis of small, exact volumes of liquid matrices much simpler. Through capillary blood microsampling, tacrolimus monitoring has potentially become …
Read StoryLearn about insights, research, case studies, and tutorials on integrating remote specimen collection, microsampling, and more!
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.